Simcere Pharmaceutical Group (SCR) Misses Q2 EPS by 2c

Simcere Pharmaceutical Group (NYSE: SCR) reported Q2 EPS of $0.08, $0.02 worse than the analyst estimate of $0.10. Revenue for the quarter came in at $83.2 million versus the consensus estimate of $86.83 million.

For earnings history and earnings-related data on Simcere Pharmaceutical Group (SCR) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Abbott beats second-quarter estimates, raises 2026 guidance
• CBL International to execute 1-for-13 reverse share split July 20
• Medtronic acquires SPR Therapeutics for $650 million